Q-omics provides the consensus-scored CROCCP4 profile across patient tissues and cancer cell-line models. CROCCP4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CROCCP4 is differentially expressed in 6, with the highest sampling consensus in LIHC. Additionally, CROCCP4 RNA expression shows 6,438 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, LIHC, and LSCC as cancer lineages where CROCCP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CROCCP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CROCCP4 survival associations across molecular data types. CROCCP4 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CROCCP4 RNA expression–survival associations across cancer types. High CROCCP4 expression shows unfavorable associations in UVM, ACC, CHOL, MESO, SKCM and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CROCCP4 RNA expression.
This table summarizes CROCCP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CROCCP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CROCCP4 shows lower tumor expression in UCEC and KIRC and higher tumor expression in LIHC, LUAD, HNSC and KIRC. The LIHC box plot shows higher CROCCP4 RNA expression in tumor versus normal tissue (log2 FC = +0.092, t-test p = .003).
This table shows molecular features associated with CROCCP4 in patient tissues and cancer cell lines. In patient samples, CROCCP4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
